Needham Downgrades Verrica Pharmaceuticals (VRCA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Brookline Capital Markets Downgrades Verrica Pharmaceuticals (VRCA) to Hold
October 2, 2024 10:30 AM EDTBrookline Capital Markets analyst Kemp Dolliver downgraded Verrica Pharmaceuticals (NASDAQ: VRCA) from Buy to Hold.
For an analyst ratings summary and ratings history on Verrica Pharmaceuticals click here. For more ratings news on Verrica Pharmaceuticals click here.
Shares of Verrica Pharmaceuticals closed at $1.37 yesterday.
... MoreVerrica Pharmaceuticals (VRCA) Announces Restructuring of Commercial Organization
October 2, 2024 7:32 AM EDTVerrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH® for the treatment of molluscum... More
